It was revealed that pharmacological PARP1 inhibitors, including ABT-888, Olaparib and nicotinamide (NAM), counteracted NAD+ depletion, precluded oxidative DNA damage, and further preserved atrial contractile dysfunction in experimental AF (Figure 3). The gene discussed is PARP1; the disease is atrial fibrillation.